Trial Profile
Immune Response to Bivalent and Tetravalent Human Papillomavirus Vaccine in HIV Infected Adults
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; Human papillomavirus vaccine recombinant quadrivalent Merck
- Indications Human papillomavirus infections
- Focus Pharmacodynamics
- Acronyms HIPAVAC
- 16 Feb 2016 Results published in the Vaccine
- 23 Nov 2013 Results published in the Journal of Infectious Diseases.
- 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.